Systems and methods are provided for generating and applying biomimicry tear film layers to a cornea surface. An example method includes forming a multiple layered tear film that are optically transparent, ultra-thin, and smoothly conforming to cornea surface. The multiple layered tear film can include a biomimicry adhesive layer, a biomimicry aqueous layer, and a biomimicry lipid layer. An atomizer/nebulizer/micronizer can be used to generate and applying the biomimicry tear film layers.

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

An electrostatic fluid delivery system is configured to deliver fluid, such as a disinfectant fluid, onto a surface by electrically charging the fluid and forming the fluid into a mist, fog, plume, or spray that can be directed onto a surface, such as a surface to be cleaned. The system atomizes the fluid using a high-pressure fluid stream and passes the fluid through an electrode of a nozzle assembly to charge droplets of the atomized fluid.

The invention relates to a fluid spray nozzle which is intended to be mounted on a distribution receptacle, the nozzle comprising at least one fluid inlet capillary extending longitudinally along an axis, a supply means to receive the fluid from the at least one inlet capillary in order to supply it to a pillar comprising at least two pipes, the pipes extending longitudinally along the axis A1 and being radially offset relative to the axis, at least two turbulence channels in fluid connection with the at least two pipes, a turbulence chamber for receiving the fluid coming tangentially from the at least two turbulence channels in order to supply at least one spray opening having axial symmetry and a constant cross-section s, the chamber having a cross-section decreasing towards the opening and having a maximum cross-section S and a maximum diameter, the ratio of the cross-section s of the spray opening to the maximum cross-section S of the turbulence chamber is 1%≤s/S≤20%.

Provided is a system including a plurality of inhalers that each include a processor configured to determine a value of a usage parameter relating to use of the respective first inhaler, encrypt data based on the value, and transmit the encrypted data. At least two of the inhalers include different medicament, such as a rescue medicament and a maintenance medicament. The system includes an external device that includes a processor configured to distinguish between the encrypted data of each respective inhaler, determine respective usage information relating to each of the distinct types of medicament based on the respective encrypted data, and control a user interface (e.g., of the external device) to communicate the usage information related to each inhaler and/or each respective type of medicament.

An aerosol generating system including a housing defining an airflow outlet; a liquid aerosol-forming substrate; an aerosol generator, configured to generate an aerosol from the liquid aerosol-forming substrate; a perforated plate disposed between the aerosol generator and the airflow outlet, the perforated plate defining a plurality of apertures extending through the perforated plate; and an electrode disposed between the aerosol generator and the perforated plate, wherein the perforated plate is electrically conductive, and wherein the electrode and the perforated plate are configured to generate an electrical potential.

Disclosed is a ratchet mechanism having ratchet ring and a chassis. The ratchet ring is rotatable about an axis relative to the chassis, with a general direction of rotation determined by teeth of the ratchet mechanism. The ratchet ring has a first set of teeth arranged regularly around the ratchet ring and protruding in a first axial direction from the ratchet ring and a second set of teeth arranged regularly around the ratchet ring and protruding in a second opposite axial direction from the ratchet ring. The chassis has a third set of teeth arranged regularly and protruding in the second axial direction and generally opposed to the first set of teeth, and a fourth set of teeth arranged regularly and protruding in the first axial direction and generally opposed to the second set of teeth.

A nozzle (10) for a container for the intranasal administration of a liquid formulation comprises a nozzle body (12) with an upper end (18) and a lower end (16), a channel (40) traversing the nozzle body (12) and ending with an orifice (17) in the upper end (18), and a nozzle cover (14) covering an area of the outer surface of the nozzle body (12) which is designed to be introduced into a user's nostril, wherein the nozzle body (12) is made out of a first material and the nozzle cover (14) is made out of a second material, said first material being a rigid plastic material, and said second material being an elastic plastic material, and wherein the nozzle cover (14) is not in contact with the orifice (17). A packaging for a liquid formulation for intranasal administration comprises a container and such nozzle (10). A product comprises such a packaging and a liquid formulation in said packaging.

Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.

A ventilation system that includes a pressure source, a pneumatic path configured to receive gas from the pressure source and comprising a first pneumatic component coupled to a second pneumatic component. The first pneumatic component includes a first electrical conductor including a first electrical component having a first electrical characteristic. The second pneumatic component comprises a second electrical conductor including a second electrical component having a second electrical characteristic. The first electrical conductor is electrically connected with the second electrical conductor in an electric path. The system performs operations including determining a continuity of the electrical path; displaying a notification regarding the continuity of the electrical path; detecting the unique electrical characteristic of the electric path; and determining a pneumatic characteristic of the pneumatic path.